UBR1 promotes protein kinase quality control and sensitizes cells to Hsp90 inhibition

Experimental Cell Research

Volumn 318, Issue 1, 2012, Pages 53-60

  Sultana, Rasheda ^a   Theodoraki, Maria A ^a   Caplan, Avrom J ^a  

^a CITY COLLEGE OF NEW YORK   (United States)

Author keywords

Hsp90; Molecular chaperone; Quality control; Ubiquitin ligase; UBR1

Indexed keywords

CYCLIN DEPENDENT KINASE 4; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEIN KINASE; PROTEIN KINASE B; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUALITY CONTROL; WILD TYPE;

MAMMALIA;

EID: 81355127301     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.09.010     Document Type: Article

References (32)

1. Balch W.E., Morimoto R.I., Dillin A., Kelly J.W. Adapting proteostasis for disease intervention. Science 2008, 319:916-919.
2. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549.
3. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.
4. Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J., Hohfeld J., Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 2001, 3:93-96.
5. Meacham G.C., Patterson C., Zhang W., Younger J.M., Cyr D.M. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat. Cell Biol. 2001, 3:100-105.
6. Fan M., Park A., Nephew K.P. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha. Mol. Endocrinol. 2005, 19:2901-2914.
7. Xu W., Marcu M., Yuan X., Mimnaugh E., Patterson C., Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:12847-12852.
8. Citri A., Alroy I., Lavi S., Rubin C., Xu W., Grammatikakis N., Patterson C., Neckers L., Fry D.W., Yarden Y. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 2002, 21:2407-2417.
9. Cardozo C.P., Michaud C., Ost M.C., Fliss A.E., Yang E., Patterson C., Hall S.J., Caplan A.J. C-terminal Hsp-interacting protein slows androgen receptor synthesis and reduces its rate of degradation. Arch. Biochem. Biophys. 2003, 410:134-140.
10. Dai Q., Zhang C., Wu Y., McDonough H., Whaley R.A., Godfrey V., Li H.H., Madamanchi N., Xu W., Neckers L., Cyr D., Patterson C. CHIP activates HSF1 and confers protection against apoptosis and cellular stress. EMBO J. 2003, 22:5446-5458.
11. Qian S.B., McDonough H., Boellmann F., Cyr D.M., Patterson C. CHIP-mediated stress recovery by sequential ubiquitination of substrates and Hsp70. Nature 2006, 440:551-555.
12. Nillegoda N.B., Theodoraki M.A., Mandal A.K., Mayo K.J., Ren H.Y., Sultana R., Wu K., Johnson J., Cyr D.M., Caplan A.J. Ubr1 and Ubr2 function in a quality control pathway for degradation of unfolded cytosolic proteins. Mol. Biol. Cell 2010, 21:2102-2116.
13. Ehrlich E.S., Wang T., Luo K., Xiao Z., Niewiadomska A.M., Martinez T., Xu W., Neckers L., Yu X.F. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20330-20335.
14. Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein Sci. 2011.
15. Heck J.W., Cheung S.K., Hampton R.Y. Cytoplasmic protein quality control degradation mediated by parallel actions of the E3 ubiquitin ligases Ubr1 and San1. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1106-1111.
16. Eisele F., Wolf D.H. Degradation of misfolded protein in the cytoplasm is mediated by the ubiquitin ligase Ubr1. FEBS Lett. 2008, 582:4143-4146.
17. Tasaki T., Mulder L.C., Iwamatsu A., Lee M.J., Davydov I.V., Varshavsky A., Muesing M., Kwon Y.T. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol. Cell. Biol. 2005, 25:7120-7136.
18. Zenker M., Mayerle J., Lerch M.M., Tagariello A., Zerres K., Durie P.R., Beier M., Hulskamp G., Guzman C., Rehder H., Beemer F.A., Hamel B., Vanlieferinghen P., Gershoni-Baruch R., Vieira M.W., Dumic M., Auslender R., Gil-da-Silva-Lopes V.L., Steinlicht S., Rauh M., Shalev S.A., Thiel C., Ekici A.B., Winterpacht A., Kwon Y.T., Varshavsky A., Reis A. Deficiency of UBR1, a ubiquitin ligase of the N-end rule pathway, causes pancreatic dysfunction, malformations and mental retardation. Nat. Genet. 2005, 37:1345-1350.
19. An J.Y., Seo J.W., Tasaki T., Lee M.J., Varshavsky A., Kwon Y.T. Impaired neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6212-6217.
20. Basso A.D., Solit D.B., Chiosis G., Giri B., Tsichlis P., Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 2002, 277:39858-39866.
21. Stepanova L., Leng X., Parker S.B., Harper J.W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev. 1996, 10:1491-1502.
22. Zou J., Guo Y., Guettouche T., Smith D.F., Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998, 94:471-480.
23. Guo W., Reigan P., Siegel D., Zirrolli J., Gustafson D., Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005, 65:10006-10015.
24. Kelland L.R., Sharp S.Y., Rogers P.M., Myers T.G., Workman P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl Cancer Inst. 1999, 91:1940-1949.
25. Caldas-Lopes E., Cerchietti L., Ahn J.H., Clement C.C., Robles A.I., Rodina A., Moulick K., Taldone T., Gozman A., Guo Y., Wu N., de Stanchina E., White J., Gross S.S., Ma Y., Varticovski L., Melnick A., Chiosis G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8368-8373.
26. Kume K., Iizumi Y., Shimada M., Ito Y., Kishi T., Yamaguchi Y., Handa H. Role of N-end rule ubiquitin ligases UBR1 and UBR2 in regulating the leucine-mTOR signaling pathway. Genes Cells 2010, 15:339-349.
27. Dickey C.A., Koren J., Zhang Y.J., Xu Y.F., Jinwal U.K., Birnbaum M.J., Monks B., Sun M., Cheng J.Q., Patterson C., Bailey R.M., Dunmore J., Soresh S., Leon C., Morgan D., Petrucelli L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3622-3627.
28. McDonough H., Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones 2003, 8:303-308.
29. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425:407-410.
30. Holmes J.L., Sharp S.Y., Hobbs S., Workman P. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2008, 68:1188-1197.
31. Mollapour M., Tsutsumi S., Truman A.W., Xu W., Vaughan C.K., Beebe K., Konstantinova A., Vourganti S., Panaretou B., Piper P.W., Trepel J.B., Prodromou C., Pearl L.H., Neckers L. Threonine 22 phosphorylation attenuates hsp90 interaction with cochaperones and affects its chaperone activity. Mol. Cell 2011, 41:672-681.
32. Rosser M.F., Washburn E., Muchowski P.J., Patterson C., Cyr D.M. Chaperone functions of the E3 ubiquitin Ligase CHIP. J Biol Chem 2007, 282:22267-22277.